Revance Therapeutics Inc ASPEN-1 Phase 3 Results Conference Call Transcript
Welcome to the Revance Therapeutics conference call to discuss top line results from its ASPEN-1 Phase III trial of DaxibotulinumtoxinA for Injection in cervical dystonia. (Operator Instructions) As a reminder, this conference is being recorded today, Wednesday, October 14, 2020.
I would now like to turn the conference over to Jeanie Herbert, Head of Investor Relations for Revance. Please go ahead.
Thank you, Shannon. With me on today's call from Revance Therapeutics are President and Chief Executive Officer, Mark Foley; Chief Financial Officer, Toby Schilke; Chief Operating Officer and President of R&D and Product Operations, Dr. Abhay Joshi; Chief Operating Officer, Aesthetics and Therapeutics, Dustin Sjuts; and Senior Vice President of Clinical Development, Dr. Roman Rubio.
This morning, Revance Therapeutics announced results from our ASPEN-1 Phase III trial of DaxibotulinumtoxinA for Injection in cervical dystonia. If you have not
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |